Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Cross Above Fifty Day Moving Average of $5.29

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP)’s share price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $5.29 and traded as high as $5.70. Aurinia Pharmaceuticals shares last traded at $5.57, with a volume of 682,487 shares.

Wall Street Analyst Weigh In

Several equities research analysts have commented on AUPH shares. StockNews.com raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Friday, March 1st. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.00.

Aurinia Pharmaceuticals Trading Up 2.0 %

The firm has a market capitalization of $801.75 million, a price-to-earnings ratio of -13.07 and a beta of 1.41. The business’s fifty day moving average is $5.32 and its 200 day moving average is $6.35. The company has a quick ratio of 5.05, a current ratio of 5.60 and a debt-to-equity ratio of 0.19.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.14. The firm had revenue of $50.30 million for the quarter, compared to the consensus estimate of $46.30 million. Aurinia Pharmaceuticals had a negative return on equity of 15.06% and a negative net margin of 32.69%. Equities analysts predict that Aurinia Pharmaceuticals Inc. will post 0.15 earnings per share for the current year.

Institutional Trading of Aurinia Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Compagnie Lombard Odier SCmA raised its stake in shares of Aurinia Pharmaceuticals by 8.7% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 25,000 shares of the biotechnology company’s stock worth $225,000 after purchasing an additional 2,000 shares in the last quarter. HighMark Wealth Management LLC grew its position in shares of Aurinia Pharmaceuticals by 3.0% in the 1st quarter. HighMark Wealth Management LLC now owns 75,196 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 2,197 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Aurinia Pharmaceuticals by 9.1% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,634 shares of the biotechnology company’s stock valued at $257,000 after purchasing an additional 2,390 shares during the period. ProShare Advisors LLC lifted its stake in Aurinia Pharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 34,464 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 2,873 shares during the last quarter. Finally, Vermillion & White Wealth Management Group LLC bought a new position in Aurinia Pharmaceuticals during the fourth quarter worth about $30,000. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.